Reviva to Participate in the UBS Global Healthcare Conference
Reviva to Participate in the UBS Global Healthcare Conference
CUPERTINO, Calif., Oct. 31, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA.
加利福尼亞州庫比蒂諾，2024年10月31日 — reviva pharmaceuticals控股公司（納斯達克：RVPH）（「Reviva」或「公司」）是一家晚期藥品公司，專注於開發旨在滿足中央神經系統（CNS）、炎症和心代謝疾病領域未滿足的醫療需求的療法。今天，reviva的創始人、總裁兼首席執行官Laxminarayan Bhat博士宣佈將參加於2024年11月11日至14日在加州蘭喬帕洛斯弗迪斯舉行的瑞銀全球醫療會議的爐邊討論。
UBS Global Healthcare Conference
Format: Fireside chat
Date: Thursday, November 14, 2024
Time: 8:00 a.m. PT
Location: Rancho Palos Verdes, CA
Webcast Link: Click Here
瑞士瑞銀全球醫療保健會議
形式：座談會
日期：2024年11月14日星期四
時間：太平洋時間上午8:00
地點：加利福尼亞州蘭喬帕洛斯維爾德
網絡直播鏈接：點擊這裏
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Reviva是一家後期生物製藥公司，致力於爲代表醫學需求和對社會、患者及其家人造成負擔的疾病開發、發現和尋求商業化的下一代治療方案。 Reviva目前的產品管道集中於中樞神經、呼吸和代謝類疾病。Reviva的產品管道目前包括兩種藥物候選，即Brilaroxazine（RP5063）和RP1208。兩者均是公司內部自行發現的新型化學實體。 Reviva已在美國，歐洲和其他幾個國家獲得了Brilaroxazine和RP1208的組成專利權。
Reviva是一家晚期生物製藥公司，致力於發現、開發並尋求商業化對於社會、患者及其家庭構成醫療需求和負擔的下一代治療方法。Reviva的當前管線專注於中樞神經系統(CNS)、炎症和心血管代謝疾病。Reviva目前的管線包括兩個藥物候選，即布瑞拉洛昔(RP5063)和RP1208。兩者均是公司在內部發現的新化學物質。Reviva已在美國、歐洲和其他幾個國家獲得了布瑞拉洛昔和RP1208的構成專利權。
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
公司聯繫人:
Reviva Pharmaceuticals Holdings，Inc.
Laxminarayan Bhat，博士
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
投資者關係聯繫人：
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
